Casdin Partners Master Fund, L.P. - 28 Feb 2025 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Director, 10%+ Owner
Signature
Casdin Partners Master Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member
Issuer symbol
LAB
Transactions as of
28 Feb 2025
Net transactions value
+$5,196,320
Form type
4
Filing time
04 Mar 2025, 20:19:51 UTC
Previous filing
29 Aug 2024
Next filing
29 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Purchase $5,134,321 +4,820,959 +8.9% $1.06 58,846,780 28 Feb 2025 See footnote F1
transaction LAB Common Stock Other $580,425 +545,000 +0.93% $1.06 59,391,780 28 Feb 2025 See footnote F1, F2
transaction LAB Common Stock Other $580,425 -545,000 -100% $1.06 0 28 Feb 2025 See footnote F2, F3
transaction LAB Common Stock Award $61,999 +58,215 +2.1% $1.06 2,806,470 28 Feb 2025 Direct F4, F5, F6, F7
holding LAB Common Stock 13,939,637 28 Feb 2025 See footnote F8
holding LAB Common Stock 2,744,219 28 Feb 2025 See footnote F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
F2 Represents a cross-trade, pursuant to which Casdin Amplify Fund, LP ("Amplify") transferred 545,000 shares of Common Stock to the Master Fund.
F3 The securities were owned directly by Amplify and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
F4 Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2025, subject to the Reporting Person's continued service through the applicable vesting date.
F5 The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $62,000 in cash compensation for services as a board member.
F6 Includes RSUs.
F7 The securities are owned directly by Eli Casdin.
F8 The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F9 The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

Remarks:

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.